Posting this under the heading it deserves: NHS criteria and how they are applied in practice — the long version Everything below is what sits behind that.
A narrow question about NHS criteria, deliberately narrow, because the broad version has been asked here four times and produced four long threads and no answer.
One question, stated units, stated method, and what I have already ruled out.
The opening post is the version of this I will quote in future. One addition.
Where the compound is supplied with a device, the device and the compound have separate availability positions and the device is more often the constraint.
Correcting an out-of-date claim in this subcategory with a source and a date is more valuable than a new topic on the same question.
Genuinely open to being wrong about this one.
Two claims get bundled together under NHS criteria and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.
Almost every disagreement in threads like this one dissolves once you say which of the two you are making.
MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.
The number is defensible. The precision I gave it is not.
I had written a reply contradicting post #6 and deleted it. Here is what survived.
I would rather this thread reach "we do not know" about NHS criteria than reach a confident answer that nobody can support when asked.
This follows post #8 rather than contradicting it.
An update on my earlier NHS criteria post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
Worth separating two things that post #6 runs together.
Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.
The strength of my opinion here exceeds the strength of my evidence.
Pharmacy practice varies between pharmacies and is not deducible from the regulatory position. Two people can honestly report opposite experiences.
Narrowing post #9, because the general version has more than one answer.
Distinguishing three things in the NHS criteria discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.
I would not lead a decision with this, but I would not ignore it either.
MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: Private prescribing in the UK: what is actually involved
Private prescribing in the UK: what is actually involved Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here actually do about Private…
|
+62 | 67 | 2.1k | 6mo |
|
MHRA statements, read directly — the long version
On the subject in the title: MHRA statements, read directly — the long version Working notes rather than a conclusion. Asking about MHRA statements directly, because I have read four threads on it and each…
|
2 | 44k | 22mo | |
|
About the UK & Ireland category
MHRA positions, NHS pathways, private prescriptions, and Irish differences. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a…
|
+3 | 7 | 357 | 3mo |
|
MHRA statements, read directly
MHRA statements, read directly Writing it up because I had to work it out twice and would rather nobody else did. Asking about MHRA statements directly, because I have read four threads on it and each…
|
+93 | 101 | 2.2k | 5mo |
|
Irish differences from the UK position
Posting this under the heading it deserves: Irish differences from the UK position Everything below is what sits behind that. Trying to establish the boundary conditions on irish differences. The general…
|
+62 | 66 | 993 | 21mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Irish differences from the UK position — what changed since
Irish differences from the UK position — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Irish differences is wrong? I ask…
|
+8 | 12 | 782 | 1d |
|
Labelling requirements for research chemicals — the long version
Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that. A narrow question about Labelling requirements for…
|
2 | 1.8k | 2mo | |
|
Follow-up: UK access routes, dated and sourced
On the subject in the title: UK access routes, dated and sourced Working notes rather than a conclusion. Regional question, dated March 2026, because everything in this category expires. The position differs…
|
+10 | 14 | 27k | 2d |
|
Coming back to: Private prescribing in the UK: what is actually involved
Private prescribing in the UK: what is actually involved Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here actually do about Private…
|
+62 | 67 | 2.1k | 6mo |
|
Pen wastage and its effect on real cost
Pen wastage and its effect on real cost Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers on pen wastage, because they…
|
+29 | 33 | 19k | 21mo |